A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope

Vaccine

Volumn 23, Issue 31, 2005, Pages 4005-4010

  Schreurs, Marco W J ^a   Kueter, Esther W M ^a   Scholten, Kirsten B J ^a   Lemonnier, François A ^b   Meijer, Chris J L M ^a   Hooijberg, Erik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUT PASTEUR   (France)

Author keywords

Altered peptide ligand; Cervical carcinoma; Immunotherapy

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; PEPTIDE; PROTEIN E7; TYROSYLMETHIONYLLEUCYLASPARTYLLEUCYLGLUTAMINYLPROLYLGLUTAMYLTHREONYL THREONINE; TYROSYLMETHIONYLLEUCYLASPARTYLLEUCYLGLUTAMINYLPROLYLGLUTAMYLTHREONYLVALINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; UTERINE CERVIX CARCINOMA; VACCINATION;

AMINO ACID SUBSTITUTION; ANIMALS; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 20444398073     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.03.014     Document Type: Article

References (12)

1. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, and K.V. Shah Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 1 1999 12 19
2. I.H. Frazer Prevention of cervical cancer through papillomavirus vaccination Nat Rev Immunol 4 1 2004 46 54
3. M.E. Ressing, A. Sette, R.M. Brandt, J. Ruppert, P.A. Wentworth, and M. Hartman Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides J Immunol 154 11 1995 5934 5943
4. M.W. Schreurs, K.B. Scholten, E.W. Kueter, J.J. Ruizendaal, C.J. Meijer, and E. Hooijberg In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones J Immunol 171 6 2003 2912 2921
5. A. Sette, A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, and W.M. Kast The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes J Immunol 153 12 1994 5586 5592
6. S. Pascolo, N. Bervas, J.M. Ure, A.G. Smith, F.A. Lemonnier, and B. Perarnau HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from β2-microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice J Exp Med 185 12 1997 2043 2051
7. H. Firat, F. Garcia-Pons, S. Tourdot, S. Pascolo, A. Scardino, and Z. Garcia H-2 class I knockout, HLA-A2. 1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies Eur J Immunol 29 10 1999 3112 3121
8. M.H. Heemskerk, E. Hooijberg, J.J. Ruizendaal, M.M. van der Weide, E. Kueter, and A.Q. Bakker Enrichment of an antigen-specific T cell response by retrovirally-transduced human dendritic cells Cell Immunol 195 1 1999 10 17
9. M.R. Betts, J.M. Brenchley, D.A. Price, S.C. De Rosa, D.C. Douek, and M. Roederer Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation J Immunol Methods 281 1-2 2003 65 78
10. V. Rubio, T.B. Stuge, N. Singh, M.R. Betts, J.S. Weber, and M. Roederer Ex vivo identification, isolation and analysis of tumor-cytolytic T cells Nat Med 9 11 2003 1377 1382
11. S.A. Rosenberg, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, and S.L. Topalian Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 3 1998 321 327
12. R. Dyall, W.B. Bowne, L.W. Weber, J. LeMaoult, P. Szabo, and Y. Moroi Heteroclitic immunization induces tumor immunity J Exp Med 188 9 1998 1553 1561